Compare Nasdaq Inc (NDAQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs GeneDx Holdings Corp — how do they compare? Nasdaq Inc trades at $94.69 (market cap $52.67B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Nasdaq Inc is far larger — about 20.4× GeneDx Holdings Corp's market cap, and Nasdaq Inc pays a 1.23% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NDAQ | WGS | |
|---|---|---|
Market Cap | $52.67B | $2.58B |
Sector | Financials | Technology |
52-Week High | $100.98 | $167.51 |
52-Week Low | $76.85 | $34.51 |
Enterprise Value | $59.12B | $2.61B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.04, down 1.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, and net income margin improved to 22.52%. Recent news highlights strategic acquisitions like Dasseti to enhance AI capabilities.
The outlook is positive with a consensus price target of $109.20, implying 15% upside. Key opportunities include continued earnings growth and expansion in data-driven investment technology. Risks involve market volatility and execution of acquisition integration. Analyst sentiment is bullish with 61% buy ratings.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
